Richard C. Young & Co’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.73K | Sell |
113,356
-15,456
| -12% | -$404K | ﹤0.01% | 101 |
|
|
2026
Q1 | $3.62M | Sell |
128,812
-68,246
| -35% | -$1.82M | 0.3% | 61 |
|
|
2025
Q4 | $4.91M | Sell |
197,058
-249,359
| -56% | -$6.29M | 0.44% | 57 |
|
|
2025
Q3 | $11.4M | Buy |
446,417
+2,741
| +0.6% | +$67.7K | 1.06% | 42 |
|
|
2025
Q2 | $10.8M | Buy |
443,676
+10,035
| +2% | +$234K | 1.06% | 44 |
|
|
2025
Q1 | $11M | Buy |
433,641
+676
| +0.2% | +$17.7K | 1.18% | 42 |
|
|
2024
Q4 | $11.5M | Sell |
432,965
-19,042
| -4% | -$517K | 1.25% | 37 |
|
|
2024
Q3 | $13.1M | Buy |
452,007
+12,818
| +3% | +$374K | 1.43% | 35 |
|
|
2024
Q2 | $12.3M | Buy |
439,189
+21,683
| +5% | +$597K | 1.49% | 34 |
|
|
2024
Q1 | $11.6M | Buy |
417,506
+224,125
| +116% | +$6.22M | 1.45% | 36 |
|
|
2023
Q4 | $5.57M | Sell |
193,381
-198,456
| -51% | -$6M | 0.75% | 55 |
|
|
2023
Q3 | $13M | Buy |
391,837
+2,125
| +0.5% | +$75.1K | 1.85% | 21 |
|
|
2023
Q2 | $14.3M | Buy |
389,712
+7,941
| +2% | +$309K | 1.96% | 21 |
|
|
2023
Q1 | $15.6M | Sell |
381,771
-1,838
| -0.5% | -$79.4K | 2.15% | 14 |
|
|
2022
Q4 | $19.7M | Sell |
383,609
-1,504
| -0.4% | -$72.1K | 2.62% | 7 |
|
|
2022
Q3 | $16.9M | Buy |
385,113
+342
| +0.1% | +$16.6K | 2.58% | 8 |
|
|
2022
Q2 | $20.2M | Buy |
384,771
+4,676
| +1% | +$238K | 2.61% | 8 |
|
|
2022
Q1 | $19.7M | Sell |
380,095
-7,076
| -2% | -$367K | 2.51% | 9 |
|
|
2021
Q4 | $22.9M | Buy |
387,171
+5,662
| +1% | +$281K | 2.88% | 7 |
|
|
2021
Q3 | $16.4M | Sell |
381,509
-1,529
| -0.4% | -$67.7K | 2.25% | 12 |
|
|
2021
Q2 | $15M | Buy |
383,038
+10,839
| +3% | +$422K | 1.91% | 15 |
|
|
2021
Q1 | $13.5M | Buy |
372,199
+25,047
| +7% | +$889K | 1.79% | 19 |
|
|
2020
Q4 | $12.8M | Sell |
347,152
-4,551
| -1% | -$167K | 1.95% | 17 |
|
|
2020
Q3 | $12.2M | Buy |
351,703
+122,518
| +53% | +$4.3M | 1.97% | 18 |
|
|
2020
Q2 | $7.11M | Sell |
229,185
-817
| -0.4% | -$27.8K | 1.18% | 34 |
|
|
2020
Q1 | $7.12M | Buy |
230,002
+22,535
| +11% | +$768K | 1.38% | 33 |
|
|
2019
Q4 | $7.71M | Buy |
207,467
+108,114
| +109% | +$3.85M | 1.28% | 40 |
|
|
2019
Q3 | $3.39M | Sell |
99,353
-107,422
| -52% | -$3.91M | 0.61% | 53 |
|
|
2019
Q2 | $8.5M | Buy |
206,775
+2,548
| +1% | +$101K | 1.61% | 26 |
|
|
2019
Q1 | $8.23M | Buy |
+204,227
| New | +$8.18M | 1.57% | 26 |
|
Other funds holding PFE
Richard C. Young & Co's PFE Position: Q2 2026 in Review
Richard C. Young & Co reduced its Pfizer (PFE) stake by 12% in Q2 2026, selling an estimated $404K and leaving 113,356 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #101.
Richard C. Young & Co first reported a position in PFE in Q1 2019 and has held it in 30 quarters since. The position peaked at $22.9M in Q4 2021. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Richard C. Young & Co held 113,356 shares of Pfizer worth $2.73K as of Q2 2026.
- Richard C. Young & Co sold 15,456 Pfizer shares in Q2 2026, an estimated $404K.
- Pfizer made up ﹤0.01% of Richard C. Young & Co's portfolio in Q2 2026, its #101 holding.
- Richard C. Young & Co first reported a position in Pfizer in Q1 2019 and has held it in 30 quarters since.
- Richard C. Young & Co's Pfizer position peaked at $22.9M in Q4 2021.
- 2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Richard C. Young & Co's 13F filing for Q2 2026, filed 28 Jul 2026.